← Leaderboards
Seth M Pollack
Northwestern University
$4,174,913
Attributed
$5,068,511
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,068,511 · 5
By mechanism
R01$3,807,861 · 3
K23$858,600 · 1
R21$402,050 · 1
Top collaborators
- Shay Bracha2 shared
- Pablo Penaloza1 shared
- Jennifer D Wu1 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsPeripheral Blood Mononuclear CellImmunotherapyClinical TrialsT-LymphocyteImmuneCancer ImmunotherapyCd4 Positive T LymphocytesSolid NeoplasmNeoplastic CellBloodEngineeringDosePhenotypeAntigen PresentationDesignAftercareViralCellsMouse ModelCancer PatientAdoptive Cell TransfersBase
Grant awards (14)
Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model$672,844
R01 · FY2025 · CA · contact PI
Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV$667,553
R01 · FY2025 · CA · contact PI
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors$466,837
R01 · FY2024 · CA · contact PI
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients$177,650
R21 · FY2024 · CA · contact PI
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors$481,578
R01 · FY2023 · CA · contact PI
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients$224,400
R21 · FY2023 · CA · contact PI
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors$491,406
R01 · FY2022 · CA · contact PI
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors$442,717
R01 · FY2021 · CA · contact PI
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors$584,926
R01 · FY2020 · CA · contact PI
Adoptive T cell Therapy for Patients with NY-ESO-1 Expressing Sarcomas$171,720
K23 · FY2017 · CA · contact PI
Adoptive T cell Therapy for Patients with NY-ESO-1 Expressing Sarcomas$171,720
K23 · FY2016 · CA · contact PI
Adoptive T cell Therapy for Patients with NY-ESO-1 Expressing Sarcomas$171,720
K23 · FY2015 · CA · contact PI
Adoptive T cell Therapy for Patients with NY-ESO-1 Expressing Sarcomas$171,720
K23 · FY2014 · CA · contact PI
Adoptive T cell Therapy for Patients with NY-ESO-1 Expressing Sarcomas$171,720
K23 · FY2013 · CA · contact PI